News Releases

November 14, 2019 11/14/2019 Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day

November 14, 2019 11/14/2019 TAKEDA ANNOUNCES LAUNCH OF EXCHANGE OFFER

November 8, 2019 11/8/2019 New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period

November 7, 2019 11/7/2019 Phase 3 Trial of NINLARO (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation

November 6, 2019 11/6/2019 Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure

November 6, 2019 11/6/2019 Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting

November 5, 2019 11/5/2019 Takeda Unveils New Dengue Vaccine Manufacturing Plant in Germany

November 5, 2019 11/5/2019 Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform

November 5, 2019 11/5/2019 TAKEDA CONTINUES STRATEGIC DIVESTITURES WITH SALE OF SELECT OTC AND NON-CORE ASSETS TO STADA FOR $660 MILLION USD

November 2019